Quoin Pharmaceuticals, Ltd. (QNRX)
Nasdaq · Healthcare · Biotechnology
$4.56+1.90%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $21.9M
- 52-week range
- $3.25 – $41.80
- 52-week change
- −42.69%
- EPS (trailing)
- −$5.67
- Analyst rating
- 1.2 Strong buy
Fiscal year to Dec 2025
- Net income
- −$15.8M
From the company’s annual report on SEC EDGAR.
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Headquarters: Ashburn, United States · 4 employees · quoinpharma.com